Skip to main content

Clinical Significance of Focal Adhesion Kinase in Resectable Pancreatic Cancer

World Journal of Surgery volume 30, pages 219–226 (2006)Cite this article

Abstract

Focal adhesion kinase (FAK) is a non-receptor, cytoplasmic protein tyrosine kinase that is involved in the regulation of cellular signaling, migration, apoptosis, and cell cycle progression. Previous reports have shown that FAK is expressed in various kinds of cancer tissues and cancer cell lines; however, no information is available about human pancreatic carcinoma specimens. Tissue such specimens were obtained from 50 patients who underwent pancreatic resection for pancreatic invasive ductal carcinoma at our institute from 1996 to 2002. Immunohistochemical analysis of FAK was performed in the resected specimens. Focal adhesion kinase expression in seven human pancreatic cancer cell lines was analyzed by reverse transcription polymerase chain reaction (PCR) analysis and Western blot analysis. Focal adhesion kinase expression was detected in 24 of 50 cases (48%). There was a statistically significant correlation between FAK expression and tumor size (P = 0.004), although FAK expression did not significantly correlate with other factors such as tumor histological grade, lymph node metastasis, distant metastasis, histological stage, and overall survival. Reverse transcription PCR analysis and Western blot analysis showed that FAK was expressed in all seven pancreatic cancer cell lines. Focal adhesion kinase expression was not directly related to clinicopathological factors except tumor size in pancreatic carcinoma. Focal adhesion kinase expression may not be a prognostic marker for pancreatic cancer patients.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

References

  1. Schaller MD, Borgman CA, Cobb BS, et al. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc Natl Acad Sci USA 1992;89:5192–5196

    CAS  PubMed  Google Scholar 

  2. Kornberg L, Earp HS, Parsons JT, et al. Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem 1992;267:23439–23442

    CAS  PubMed  Google Scholar 

  3. Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev. 2003;22:359–374

    Article  CAS  PubMed  Google Scholar 

  4. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000;2:249–256

    CAS  PubMed  Google Scholar 

  5. Cance WG, Harris JE, Iacocca MV, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res 2000;6:2417–2423

    CAS  PubMed  Google Scholar 

  6. Owens LV, Xu L, Dent GA, et al. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol 1996;3:100–105

    CAS  PubMed  Google Scholar 

  7. Agochiya M, Brunton VG, Owens DW, et al. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene 1999;18:5646–5653

    Article  CAS  PubMed  Google Scholar 

  8. Judson PL, He X, Cance WG, et al. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 1999;86:1551–1556

    Article  CAS  PubMed  Google Scholar 

  9. Miyazaki T, Kato H, Nakajima M, et al. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 2003;89:140–145

    Article  CAS  PubMed  Google Scholar 

  10. Mori T, Doi R, Koizumi M, et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 2004;3:29–37

    PubMed  Google Scholar 

  11. Schaller MD, Hildebrand JD, Shannon JD, et al. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 1994;14:1680–1688

    CAS  PubMed  Google Scholar 

  12. Chen HC, Guan JL. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 1994;91:10148–10152

    CAS  PubMed  Google Scholar 

  13. Zhang X, Chattopadhyay A, Ji QS, et al. Focal adhesion kinase promotes phospholipase C-gamma1 activity. Proc Natl Acad Sci USA 1999;96:9021–9026

    CAS  PubMed  Google Scholar 

  14. Han DC, Guan JL. Association of focal adhesion kinase with Grb7 and its role in cell migration. J. Biol. Chem. 1999;274:24425–24430

    CAS  PubMed  Google Scholar 

  15. Itoh S, Maeda T, Shimada M, et al. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res 2004;10:2812–2817

    CAS  PubMed  Google Scholar 

  16. Su JM, Gui L, Zhou YP, et al. Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance. World J Gastroenterol 2002;8:613–618

    CAS  PubMed  Google Scholar 

  17. Kornberg LJ. Focal adhesion kinase expression in oral cancers. Head Neck 1998;20:634–639

    CAS  PubMed  Google Scholar 

  18. Wang D, Grammer JR, Cobbs CS, et al. p125 Focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo. J Cell Sci 2000;113(Pt 23):4221–4230

    Google Scholar 

  19. Gabarra-Niecko V, Keely PJ, Schaller MD. Characterization of an activated mutant of focal adhesion kinase: ‘SuperFAK’. Biochem J 2002;365(Pt 3):591–603

    Google Scholar 

  20. Aguirre Ghiso JA. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002;21:2513–2524

    Article  PubMed  Google Scholar 

  21. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990;211:447–458

    CAS  PubMed  Google Scholar 

  22. Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater—results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993;29A:698–703

    CAS  PubMed  Google Scholar 

  23. Sohn TA, Campbell KA, Pitt HA, et al. Quality of life and long-term survival after surgery for chronic pancreatitis. J Gastrointest Surg 2000;4:355–364; discussion 364–355

    CAS  PubMed  Google Scholar 

  24. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999;65:618–623; discussion 623–614

    CAS  PubMed  Google Scholar 

  25. Meyer W, Jurowich C, Reichel M, et al. Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today 2000;30:582–587

    Article  CAS  PubMed  Google Scholar 

  26. Duxbury MS, Ito H, Benoit E, et al. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 2003;311:786–792

    Article  CAS  PubMed  Google Scholar 

  27. Duxbury MS, Ito H, Zinner MJ, et al. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 2004;135:555–562

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants-in-aid 17390364 and 17659409 from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Author information

Affiliations

  1. Department of Surgery and Surgical Basic Science, Kyoto University, 54 Shogoinkawaracho, Sakyo, Kyoto, 606-8507, Japan

    Kenichiro Furuyama MD, Ryuichiro Doi MD, Tomohiko Mori MD, Eiji Toyoda MD, Daisuke Ito MD, Kazuhiro Kami MD, Masayuki Koizumi MD, Atsushi Kida MD, Yoshiya Kawaguchi MD & Koji Fujimoto MD

Authors
  1. Kenichiro Furuyama MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryuichiro Doi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomohiko Mori MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eiji Toyoda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daisuke Ito MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiro Kami MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masayuki Koizumi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Atsushi Kida MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshiya Kawaguchi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Koji Fujimoto MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryuichiro Doi MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Furuyama, K., Doi, R., Mori, T. et al. Clinical Significance of Focal Adhesion Kinase in Resectable Pancreatic Cancer. World J. Surg. 30, 219–226 (2006). https://doi.org/10.1007/s00268-005-0165-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-005-0165-z

Keywords

  • Pancreatic Cancer
  • Focal Adhesion Kinase
  • Pancreatic Cancer Cell Line
  • Pancreatic Cancer Patient
  • Acinar Cell Carcinoma